Huot P[au] - Search Results

Year	Number of Results
1996	1
1997	4
2006	2
2007	4
2008	3
2009	1
2010	7
2011	8
2012	9
2013	9
2014	6
2015	15
2016	8
2017	7
2018	10
2019	6
2020	14
2021	12
2022	13
2023	4

1

Cognition and serotonin in Parkinson's disease.

Frouni I, Kwan C, Belliveau S, Huot P. Frouni I, et al. Among authors: huot p. Prog Brain Res. 2022;269(1):373-403. doi: 10.1016/bs.pbr.2022.01.013. Epub 2022 Feb 4. Prog Brain Res. 2022. PMID: 35248202 Review.

2

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic.

Sharifian-Dorche M, Huot P, Osherov M, Wen D, Saveriano A, Giacomini PS, Antel JP, Mowla A. Sharifian-Dorche M, et al. Among authors: huot p. J Neurol Sci. 2020 Oct 15;417:117085. doi: 10.1016/j.jns.2020.117085. Epub 2020 Aug 7. J Neurol Sci. 2020. PMID: 32871412 Free PMC article. Review.

3

Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.

Huot P, Kang W, Kim E, Bédard D, Belliveau S, Frouni I, Kwan C. Huot P, et al. Neurodegener Dis Manag. 2022 Apr;12(2):51-55. doi: 10.2217/nmt-2021-0051. Epub 2021 Dec 23. Neurodegener Dis Manag. 2022. PMID: 34939425 Review. No abstract available.

4

Monoamine oxidase A inhibition and Parkinson's disease.

Huot P. Huot P. Neurodegener Dis Manag. 2020 Dec;10(6):335-337. doi: 10.2217/nmt-2020-0043. Epub 2020 Aug 27. Neurodegener Dis Manag. 2020. PMID: 32847468 No abstract available.

5

An overview of the active clinical trials for Parkinson's disease psychosis.

Kwan C, Huot P. Kwan C, et al. Among authors: huot p. Neurodegener Dis Manag. 2022 Aug;12(4):165-170. doi: 10.2217/nmt-2022-0020. Epub 2022 May 20. Neurodegener Dis Manag. 2022. PMID: 35592949 Review.

6

Pemphigoid-like Skin Lesions Following Introduction of Safinamide.

Lachance L, Huot P. Lachance L, et al. Among authors: huot p. Can J Neurol Sci. 2022 Jun 13:1-2. doi: 10.1017/cjn.2022.75. Online ahead of print. Can J Neurol Sci. 2022. PMID: 35695178 No abstract available.

7

5-HT_1A agonists and dyskinesia in Parkinson's disease: a pharmacological perspective.

Huot P. Huot P. Neurodegener Dis Manag. 2018 Aug;8(4):207-209. doi: 10.2217/nmt-2018-0017. Epub 2018 Jul 24. Neurodegener Dis Manag. 2018. PMID: 30040029 Free article. Review. No abstract available.

8

5-HT₃ receptors in Parkinson's disease psychosis: a forgotten target?

Kwan C, Huot P. Kwan C, et al. Among authors: huot p. Neurodegener Dis Manag. 2019 Oct;9(5):251-253. doi: 10.2217/nmt-2019-0014. Neurodegener Dis Manag. 2019. PMID: 31580227 No abstract available.

9

5-HT_2A receptors and Parkinson's disease psychosis: a pharmacological discussion.

Huot P. Huot P. Neurodegener Dis Manag. 2018 Dec;8(6):363-365. doi: 10.2217/nmt-2018-0039. Epub 2018 Nov 19. Neurodegener Dis Manag. 2018. PMID: 30451579 Free article. No abstract available.

10

Classic animal models of Parkinson's disease: a historical perspective.

Hamadjida A, Frouni I, Kwan C, Huot P. Hamadjida A, et al. Among authors: huot p. Behav Pharmacol. 2019 Jun;30(4):291-310. doi: 10.1097/FBP.0000000000000441. Behav Pharmacol. 2019. PMID: 30216234 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results